Mobile Application for Bioanalytical Assays in the Industry
PharmaNet/i3
, inVentiv Health’s clinical segment and a provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that it is offering a mobile application in the CRO industry for bioanalytical assays. The application will provide clients the ability to search the Company’s more than 1000 bioanalytical assays from an iPhone®, iPad®, or Android™ Smartphone.
“Bioanalytical assays are used to quantitate drugs and their metabolites in a variety of matrices and are critical to the testing of new drug candidates and clinical trials,” said Farah Ahmad, Executive Director, Business Development.
“In addition to the scientific strength of our bioanalytical team and our technology platforms, this application will afford the ease of use that ourclients are seeking; it provides instant access to information from anywhere.” added Ms. Ahmad.
To access the application:
· iPad®, iPhone®:
http://itunes.apple.com/app/pharmanet-i3-bioanalytical/id577099615?mt=8
· Android™:
https://play.google.com/store/apps/details?id=com.pharmanet.Pharmanet
iPad® and iPhone® are registered trademarks of Apple Inc. Android™ is a trademark of GoogleInc.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
